$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

$clov Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000180117022000083 Filed on November 07, 2022

Income Statement

Concept	2022 Q3	2021 Q4
Revenue	$856.8M	$432.0M
YoY Change	100.58%
Cost Of Revenue	$839.8M
YoY Change	92.43%
Gross Profit	$17.02M
YoY Change	-283.8%
Gross Profit Margin	1.99%
Selling, General & Admin	$118.0M	$114.2M
YoY Change	-0.96%
% of Gross Profit	693.23%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$616.0K	$848.0K
YoY Change	413.33%
% of Gross Profit	3.62%
Operating Expenses	$930.7M	$618.8M
YoY Change	61.47%	13964.2%
Operating Profit	-$73.92M
YoY Change	-50.48%
Interest Expense	$404.0K	-$412.0K
YoY Change	-2.18%
% of Operating Profit
Other Income/Expense, Net	-$9.000K	$0.00
YoY Change	-30.77%
Pretax Income	-$75.31M	-$187.2M
YoY Change	118.11%	4154.57%
Income Tax
% Of Pretax Income
Net Earnings	-$75.31M	-$187.2M
YoY Change	118.11%	4154.57%
Net Earnings / Revenue	-8.79%	-43.33%
Basic Earnings Per Share	-$0.16
Diluted Earnings Per Share	-$0.16	-$445.3K
COMMON SHARES
Basic Shares Outstanding	477.7M shares
Diluted Shares Outstanding	477.7M shares

Balance Sheet

Concept	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$558.0M	$321.1M
YoY Change	149.76%	247.71%
Cash & Equivalents	$382.9M	$300.0M
Short-Term Investments	$175.1M	$21.13M
Other Short-Term Assets	$36.78M	$18.02M
YoY Change	526.5%	5927.42%
Inventory
Prepaid Expenses	$17.82M	$9.409M
Receivables
Other Receivables
Total Short-Term Assets	$1.460B	$752.5M
YoY Change	161.05%	296.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.526M	$2.287M
YoY Change	16.3%	10.06%
Goodwill		$1.200M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$970.0K	$0.00
YoY Change	-99.34%	-100.0%
Other Assets	$14.76M	$10.43M
YoY Change	8.12%	17.41%
Total Long-Term Assets	$97.69M	$198.3M
YoY Change	-75.16%	155.92%
TOTAL ASSETS
Total Short-Term Assets	$1.460B	$752.5M
Total Long-Term Assets	$97.69M	$198.3M
Total Assets	$1.558B	$950.8M
YoY Change	63.54%	255.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$37.74M	$28.13M
YoY Change	55.88%
Accrued Expenses	$21.64M	$18.21M
YoY Change	26.05%	268.94%
Deferred Revenue	$96.36M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$1.128B	$372.6M
YoY Change	390.05%	126.89%
LONG-TERM LIABILITIES
Long-Term Debt	$19.97M	$19.94M
YoY Change	0.18%	-81.26%
Other Long-Term Liabilities	$13.12M	$14.10M
YoY Change	-67.68%	7.46%
Total Long-Term Liabilities	$33.09M	$34.03M
YoY Change	-45.33%	-71.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.128B	$372.6M
Total Long-Term Liabilities	$33.09M	$34.03M
Total Liabilities	$1.166B	$411.5M
YoY Change	115.8%	-4.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.872B	-$1.617B
YoY Change	30.92%	57.12%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$147.0K
YoY Change
Treasury Stock Shares		14.73K shares
Shareholders Equity	$392.0M	$535.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.558B	$950.8M
YoY Change	63.54%	255.77%

Cashflow Statement

Concept	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$75.31M	-$187.2M
YoY Change	118.11%	4154.57%
Depreciation, Depletion And Amortization	$616.0K	$848.0K
YoY Change	413.33%
Cash From Operating Activities	$101.7M	-$80.18M
YoY Change	-325.27%	6995.22%
INVESTING ACTIVITIES
Capital Expenditures	-$259.0K	-$238.0K
YoY Change	32.82%
Acquisitions
YoY Change
Other Investing Activities	-$43.13M	-$106.3M
YoY Change	-82.19%
Cash From Investing Activities	-$43.39M	-$106.5M
YoY Change	-82.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	132.0K	284.4M
YoY Change	-96.69%	880.59%
NET CHANGE
Cash From Operating Activities	101.7M	-80.18M
Cash From Investing Activities	-43.39M	-106.5M
Cash From Financing Activities	132.0K	284.4M
Net Change In Cash	58.40M	97.70M
YoY Change	-120.6%	250.57%
FREE CASH FLOW
Cash From Operating Activities	$101.7M	-$80.18M
Capital Expenditures	-$259.0K	-$238.0K
Free Cash Flow	$101.9M	-$79.94M
YoY Change	-326.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001801170
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Registrant Name EntityRegistrantName	CLOVER HEALTH INVESTMENTS, CORP. /DE
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39252
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1515192
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3401 Mallory Lane
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	Franklin
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37067
	dei	City Area Code CityAreaCode	201
	dei	Local Phone Number LocalPhoneNumber	432-2133
	dei	Security12g Title Security12gTitle	Class A Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	CLOV
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382869000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	299968000	usd
CY2022Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	153799000	usd
CY2021Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	293851000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	179774000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	21142000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	175116000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21131000	usd
CY2022Q3	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	0	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	307000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	0	usd
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	305000	usd
CY2022Q3	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	13894000	usd
CY2021Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	34923000	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	23085000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	14282000	usd
CY2022Q3	us-gaap	Receivables From Customers ReceivablesFromCustomers	58886000	usd
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	48042000	usd
CY2022Q3	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	585901000	usd
CY2021Q4	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	0	usd
CY2022Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	11844000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12613000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	17816000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9409000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	36782000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18022000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1459992000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	752546000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	76339000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	177527000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	70237000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	175604000	usd
CY2022Q3	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	596000	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	364000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	700000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	335000	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	970000	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2526000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2287000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4259000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5367000	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	4233000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	4233000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14762000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10432000	usd
CY2022Q3	us-gaap	Assets Assets	1557679000	usd
CY2021Q4	us-gaap	Assets Assets	950804000	usd
CY2022Q3	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	140276000	usd
CY2021Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	138604000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1661000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2320000	usd
CY2022Q3	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	655849000	usd
CY2021Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	36891000	usd
CY2022Q3	clov	Non Insurance Payable Current NonInsurancePayableCurrent	147132000	usd
CY2021Q4	clov	Non Insurance Payable Current NonInsurancePayableCurrent	37773000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37735000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28129000	usd
CY2022Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	19636000	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	15147000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	96358000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2000000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3059000	usd
CY2022Q3	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	27657000	usd
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	110628000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	73000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1128346000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	372624000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19965000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19938000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4267000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4830000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13121000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14095000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1165699000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	411487000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2280697000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2154187000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10760000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1934000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1871536000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1616738000	usd
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2041948	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	14730	shares
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6467000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	147000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	391980000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	535414000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	0	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	3903000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	391980000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	539317000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1557679000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	950804000	usd
CY2022Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned	116000	usd
CY2021Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned	120000	usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned	354000	usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned	370000	usd
CY2022Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	267892000	usd
CY2021Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	203657000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	814566000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	598390000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	585311000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	222647000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1757579000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	439020000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	3614000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	859000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	5751000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	2550000	usd
CY2022Q3	us-gaap	Revenues Revenues	856817000	usd
CY2021Q3	us-gaap	Revenues Revenues	427163000	usd
	us-gaap	Revenues Revenues	2577896000	usd
	us-gaap	Revenues Revenues	1039960000	usd
CY2022Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	839799000	usd
CY2021Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	436325000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	2560307000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1109248000	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	70142000	usd
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	73364000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	209724000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	201555000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47832000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45846000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	152569000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	130110000	usd
CY2022Q3	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-27657000	usd
CY2021Q3	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	20761000	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-82971000	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	48661000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	616000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	120000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2028000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000	usd
CY2022Q3	us-gaap	Other General Expense OtherGeneralExpense	0	usd
CY2021Q3	us-gaap	Other General Expense OtherGeneralExpense	0	usd
	us-gaap	Other General Expense OtherGeneralExpense	0	usd
	us-gaap	Other General Expense OtherGeneralExpense	191000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	930732000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	576416000	usd
	us-gaap	Operating Expenses OperatingExpenses	2841657000	usd
	us-gaap	Operating Expenses OperatingExpenses	1490163000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-73915000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-149253000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-263761000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-450203000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-115152000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66146000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	404000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	404000	usd
	us-gaap	Interest Expense InterestExpense	1197000	usd
	us-gaap	Interest Expense InterestExpense	2790000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9000	usd
CY2021Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	27000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13708000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-980000	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	10187000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-75308000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-34527000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-254798000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-400555000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	477690204	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	477690204	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	414572706	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	414572706	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475609571	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	475609571	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	410417493	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	410417493	shares
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2407000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-197000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-8826000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-620000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77715000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34724000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-263624000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-401175000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-613193000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1282000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	usd
CY2021Q2	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42713000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-493000	usd
CY2021Q1	clov	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	139444346	shares
CY2021Q1	clov	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	447747000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	447747000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16059000	usd
CY2021Q1	clov	Stock Issued During Period Value Business Combination And Offering StockIssuedDuringPeriodValueBusinessCombinationAndOffering	666242000	usd
CY2021Q1	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2021Q1	clov	Capital Contribution For Extinguishment Of Debt CapitalContributionForExtinguishmentOfDebt	126795000	usd
CY2021Q1	clov	Acquisition Of Public And Private Placement Warrants AcquisitionOfPublicAndPrivatePlacementWarrants	147582000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-48417000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	588935000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	435000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43026000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-317611000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	314855000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3830000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46803000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-197000	usd
CY2021Q3	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	147000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-34527000	usd
CY2021Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	412290000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	539317000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	331000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40640000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5324000	usd
CY2022Q1	clov	Conversion From Class A To Class B Common Stock ConversionFromClassAToClassBCommonStock	0	usd
CY2022Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1879063	shares
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5939000	usd
CY2022Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75309000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	489813000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	563000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41927000	usd
CY2022Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	37744	shares
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	105000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1095000	usd
CY2022Q2	clov	Conversion From Class A To Class B Common Stock ConversionFromClassAToClassBCommonStock	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-104181000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	426922000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	408000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42641000	usd
CY2022Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	110411	shares
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	276000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2407000	usd
CY2022Q3	clov	Conversion From Class A To Class B Common Stock ConversionFromClassAToClassBCommonStock	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-75308000	usd
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	391980000	usd
	us-gaap	Profit Loss ProfitLoss	-254798000	usd
	us-gaap	Profit Loss ProfitLoss	-400555000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2028000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	27000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13708000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	125211000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132542000	usd
	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	0	usd
	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	-66146000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-730000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	142000	usd
	clov	Realized Investment Losses Gains RealizedInvestmentLossesGains	-18000	usd
	clov	Realized Investment Losses Gains RealizedInvestmentLossesGains	-55000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	10187000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-82971000	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	48661000	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	21029000	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	4645000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	8803000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9759000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-769000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	13165000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8407000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4347000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	19263000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10291000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10844000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4089000	usd
	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1750000	usd
	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	2636000	usd
	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	1013000	usd
	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	36465000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9606000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1386000	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	4489000	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	9458000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	96358000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1005000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1013000	usd
	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	33057000	usd
	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	23861000	usd
	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	109359000	usd
	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	26233000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2264000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3179000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5442000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-202150000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	276848000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	705598000	usd
	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	9710000	usd
	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	usd
	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	350455000	usd
	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	250265000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	590000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	485000	usd
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	250000	usd
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	82477000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-328956000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30925000	usd
	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	1302000	usd
	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	5547000	usd
	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	0	usd
	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	666242000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	390000	usd
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	usd
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	85000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6320000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	147000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5018000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	641022000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82901000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	109916000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92348000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382869000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202264000	usd
	clov	Performance Year Receivable PerformanceYearReceivable	585901000	usd
	clov	Performance Year Receivable PerformanceYearReceivable	220738000	usd
	clov	Performance Year Obligation Non Cash Activities PerformanceYearObligationNonCashActivities	585901000	usd
	clov	Performance Year Obligation Non Cash Activities PerformanceYearObligationNonCashActivities	220738000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	447747000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	16059000	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	126795000	usd
	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	0	usd
	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	97782000	usd
	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	0	usd
	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	147582000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	642000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	582000	usd
	us-gaap	Transfer To Investments TransferToInvestments	8644000	usd
	us-gaap	Transfer To Investments TransferToInvestments	0	usd
	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	0	usd
	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	250000	usd
	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	0	usd
CY2022Q3	clov	Direct Contracting Shared Savings And Losses Percent DirectContractingSharedSavingsAndLossesPercent	1.000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, goodwill and other intangible assets, reinsurance, premium deficiency reserve, warrants, embedded derivative related to convertible securities, stock-based compensation, recoveries from third parties for coordination of benefits, Direct Contracting benchmark, specifically cost trend and risk score estimates that can develop over time, and final determination of medical cost adjustment pools.</span></div>
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums earned, net is recognized as income in the period members are entitled to receive services, risk adjustment revenue, and other ancillary income. Premiums received in advance of the service period are reported as deferred revenue on the Condensed Consolidated Balance Sheets and recognized within Premiums earned, net once earned. Premiums anticipated to be received within twelve months based on the documented diagnostic criteria of the Company's members are estimated and included in revenue for the period including the member months for which the payment is designated by CMS.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	700000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	104000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	596000	usd
CY2022Q3	us-gaap	Investments Investments	256813000	usd
CY2022Q3	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	usd
CY2022Q3	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10886000	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	245949000	usd
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	640000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	40000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	9000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	671000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	198669000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1944000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196735000	usd
CY2021Q4	us-gaap	Investments Investments	199309000	usd
CY2021Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	50000	usd
CY2021Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1953000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	197406000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	179774000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	175116000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	590000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	502000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	76339000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	70237000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount	110000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue	94000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	700000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	10886000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	36	position
CY2022Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	596000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	256113000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	245353000	usd
CY2022Q3	us-gaap	Net Investment Income NetInvestmentIncome	2850000	usd
CY2021Q3	us-gaap	Net Investment Income NetInvestmentIncome	179000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	3625000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	340000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	161001000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	4966000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	65926000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5920000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	214300000	usd
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	18	position
CY2022Q3	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	54	position
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	187251000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	1555000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	7902000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	398000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	195153000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	1953000	usd
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	18	position
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	4	position
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	22	position
CY2021Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	3829000	usd
CY2021Q3	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	89997000	usd
	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	9710000	usd
	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	usd
CY2022Q3	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	60000000	usd
CY2021Q3	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	50000000	usd
	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	350455000	usd
	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	250265000	usd
CY2022Q3	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	0	usd
CY2021Q3	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	8000	usd
	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	5000	usd
	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	25000	usd
CY2022Q3	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	2000	usd
CY2021Q3	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	0	usd
	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	23000	usd
	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	80000	usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-2000	usd
CY2021Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	8000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-18000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-55000	usd
CY2022Q3	us-gaap	Deposits Deposits	14200000	usd
CY2021Q4	us-gaap	Deposits Deposits	11100000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	245353000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196735000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	196735000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2022Q3	us-gaap	Receivables From Customers ReceivablesFromCustomers	58900000	usd
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	48000000	usd
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the liability for unpaid claims, including claims adjustment expenses, for the nine months ended September 30, 2022 and 2021, is summarized as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,095 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, end of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,420 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt double #ffffff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes amounts due to related parties. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Differs from the total unpaid claims amount reported on the Condensed Consolidated Balance Sheets due to the fact the figure here excludes unpaid claims for the Company's Non-Insurance operations of $6.5 million and $4.6 million as of September 30, 2022 and December 31, 2021, respectively.</span></div>
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	136317000	usd
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	103976000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	773530000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	617035000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-36149000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	17095000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	737381000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	634130000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	649223000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	494045000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	89055000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	109362000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	738278000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	603407000	usd
CY2022Q3	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	135420000	usd
CY2021Q3	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	134699000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	89100000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-36100000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	17100000	usd
	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.839
	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.801
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	20000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	20000000	usd
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2041948	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	14730	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.000
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.040
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.040
CY2022Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	usd
CY2021Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	900000	usd
	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1.000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42600000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	125200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	132500000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42641000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46803000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	125208000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	132542000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	381000000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y11M15D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.36
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	800000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M14D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21039422	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	800000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M14D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	36400000	usd
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	139629	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.61
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	122052	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.45
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q3	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-75308000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-34527000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75308000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34527000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	477690204	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	477690204	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	414572706	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	414572706	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Net Income Loss NetIncomeLoss	-254798000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-400555000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-254798000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-400555000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	475609571	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475609571	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	410417493	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	410417493	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100323307	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54584553	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100323307	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54584553	shares
CY2022Q3	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	585901000	usd
CY2021Q3	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	220738000	usd
CY2022Q3	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	655849000	usd
CY2021Q3	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	244599000	usd
CY2022Q3	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	593020000	usd
	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	1757702000	usd
CY2022Q3	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	593020000	usd
	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	1757702000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	585311000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1757579000	usd
CY2021Q3	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	223309000	usd
	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	441476000	usd
CY2021Q3	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	223309000	usd
	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	441476000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	222647000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	439020000	usd
CY2021Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned	120000	usd
CY2021Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	203657000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned	116000	usd
CY2022Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	267892000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	585311000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	3614000	usd
CY2022Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	839799000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	17018000	usd
CY2022Q3	us-gaap	Assets Assets	1557679000	usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned	354000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	814566000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1757579000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	5751000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	2560307000	usd
	us-gaap	Gross Profit GrossProfit	17589000	usd
CY2022Q3	us-gaap	Assets Assets	1557679000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	222647000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	859000	usd
CY2021Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	436325000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	-9162000	usd
CY2021Q3	us-gaap	Assets Assets	952478000	usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned	370000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	598390000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	439020000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	2550000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1109248000	usd
	us-gaap	Gross Profit GrossProfit	-69288000	usd
CY2021Q3	us-gaap	Assets Assets	952478000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	17018000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	-9162000	usd
	us-gaap	Gross Profit GrossProfit	17589000	usd
	us-gaap	Gross Profit GrossProfit	-69288000	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	70142000	usd
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	73364000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	209724000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	201555000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47832000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45846000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	152569000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	130110000	usd
CY2022Q3	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-27657000	usd
CY2021Q3	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	20761000	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-82971000	usd
	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	48661000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	616000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	120000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2028000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000	usd
CY2022Q3	us-gaap	Other General Expense OtherGeneralExpense	0	usd
CY2021Q3	us-gaap	Other General Expense OtherGeneralExpense	0	usd
	us-gaap	Other General Expense OtherGeneralExpense	0	usd
	us-gaap	Other General Expense OtherGeneralExpense	191000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-115152000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66146000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	404000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	404000	usd
	us-gaap	Interest Expense InterestExpense	1197000	usd
	us-gaap	Interest Expense InterestExpense	2790000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9000	usd
CY2021Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	27000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13708000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-980000	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	10187000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-75308000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-34527000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-254798000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-400555000	usd

Files In Submission

Name	View Source	Status
0001801170-22-000083-index-headers.html	Edgar Link	pending
0001801170-22-000083-index.html	Edgar Link	pending
0001801170-22-000083.txt	Edgar Link	pending
0001801170-22-000083-xbrl.zip	Edgar Link	pending
a09302022-exx101.htm	Edgar Link	pending
a09302022-exx102.htm	Edgar Link	pending
a09302022-exx311.htm	Edgar Link	pending
a09302022-exx312.htm	Edgar Link	pending
a09302022-exx321.htm	Edgar Link	pending
a09302022-exx322.htm	Edgar Link	pending
atsignature.jpg	Edgar Link	pending
clov-20220930.htm	Edgar Link	pending
clov-20220930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
line.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
clov-20220930_cal.xml	Edgar Link	unprocessable
clov-20220930_def.xml	Edgar Link	unprocessable
clov-20220930_lab.xml	Edgar Link	unprocessable
clov-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clov-20220930_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
redacted.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
viveksignature.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2022 Q3 Form 10-Q Financial Statement

#000180117022000083 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2022 Q3 Form 10-Q Financial Statement

#000180117022000083 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov